Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10872916 | 0.78 | ALDH1A1 (0.40) | ALDH1A1CYP1A2TSHR | |
| SCHEMBL1911564 | 0.78 | — | — | |
| SCHEMBL262553 | 0.76 | DDAH1 (0.35) | DDAH1CYP1A2TSHRTP53 | |
| SCHEMBL19691930 | 0.74 | CA12 (0.33) | ALDH1A1 | |
| SCHEMBL2592393 | 0.73 | CYP1A2 (0.37) | CYP1A2TSHRTP53LTA4H | |
| SCHEMBL93138 | 0.73 | HDAC1 (0.46) | ALDH1A1CYP1A2TSHRTP53 | |
| SCHEMBL13695048 | 0.73 | HSD17B10 (0.36) | ALDH1A1DDAH1TSHR | |
| SCHEMBL7975676 | 0.72 | ALDH1A1 (0.33) | ALDH1A1DDAH1 | |
| SCHEMBL29781019 | 0.71 | ALDH1A1 (0.38) | ALDH1A1DDAH1TSHR | |
| Ammonia Solution, Strong SCHEMBL29239960 | 0.71 | HDAC1 (0.43) | ALDH1A1CYP1A2TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-0542708-B1 | Substituted beta-amino acid derivatives useful as platelet aggregation inhibitors | MONSANTO CO (US) | 2001-05-30 | — | — | EP | disclosed |
| US-5973003-A | TREATMENT OF THROMBOSIS, STROKE, MYOCARDIAL INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS | G. D. SEARLE & CO. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5703125-A | MELT BLEND OF SOAP, SURFACTANT AND SOLVENT | G. D. SEARLE & CO. (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0614360-B1 | SUBSTITUTED BETA-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | SEARLE & CO (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0614360-A1 | SUBSTITUTED -g(b)-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS. | SEARLE & CO (US) | 1994-09-14 | — | — | EP | disclosed |
| US-5344957-A | Amidinoiphenyl-substituted | G.D. SEARLE & CO. (US) | 1994-09-06 | — | — | US | disclosed |
| EP-0542708-A1 | Substituted B-amino acid derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1993007867-A1 | SUBSTITUTED β-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | ALDH1A1 4635/4885DDAH1 2543/4885CYP1A2 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.